COMy 2023 | Disease staging systems in multiple myeloma and how these have evolved over the years
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, shares some insights into the importance of disease staging systems in multiple myeloma, and further discusses how these have evolved over the years. Dr Kumar first highlights the International Staging System (ISS) and the Revised ISS (R-ISS), and comments on the value of incorporating genetic prognostic factors into these. Dr Kumar then shares some insights into more recent staging systems, including the R2-ISS and the Mayo Additive Staging System (MASS), and where these may fit in clinical practice. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding for clinical trials to the institution: Abbvie, Amgen, Allogene, BMS, Carsgen, GSK, Janssen, Roche-Genentech, Takeda, Regeneron
Consulting/Advisory Board participation: (with no personal payments) Abbvie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, Beigene, and (with personal payment) Oncopeptides, Antengene
